![THYMALIN [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/thymalin.jpg)
$50.00
Thymalin is a multi-component polypeptide extract from calf thymus, studied mainly in Russian research for immune regulation and thymic support. Its human evidence is limited and has not been widely replicated in large independent trials. A research-grade vial is not equivalent to a regionally approved pharmaceutical product.
For laboratory research only. Not for human or animal consumption.
VIP Peptides · Research Compound
Thymalin is a polypeptide complex extracted from bovine thymus tissue.
Associated with the Russian bioregulator research tradition, it is a
multi-component extract rather than a single defined synthetic peptide.
This profile covers research-grade material.
Product Information
Unlike a single-sequence synthetic peptide such as Thymosin
Alpha-1, Thymalin is described as a complex of short peptides
isolated from calf thymus. The supplied information mentions
dipeptides such as EW (Glu-Trp) and KE.
Proposed research actions include effects on T-cell maturation
and differentiation, CD4/CD8 balance, innate and adaptive immune
activity, and cytokine signaling. These proposed actions do not
establish clinical effectiveness.
| Product | Thymalin |
|---|---|
| Source | Bovine thymus tissue |
| Product type | Multi-component polypeptide extract |
| Source vial size | Commonly described as 10 mg |
| Research tradition | Russian peptide bioregulator research |
| US regulatory status | Not FDA-approved for any indication |
Evidence & Research
Laboratory and clinical literature has examined T-cell
differentiation and maturation, including changes in markers
associated with mature T cells. Some studies also report changes
in immune parameters such as CD4/CD8 ratios.
Proposed research effects include modulation of innate and
adaptive immune activity and cytokine production, including
support for some Th1-type responses and changes in certain
pro-inflammatory signals.
Russian clinical literature describes use in contexts including
immune dysfunction, chronic infections, recovery after
chemotherapy or radiation, and age-related immune decline.
These reports do not establish effectiveness for those conditions
under independent, large-scale trials.
A small Russian clinical study reported changes in inflammatory
markers, including IL-6, CRP and D-dimer, when Thymalin was added
to standard care. This finding is preliminary and does not
establish it as a COVID-19 treatment.
Russian observational research in older adults, sometimes involving
Thymalin alongside Epitalon or Epithalamin, has reported lower
all-cause mortality over multi-year follow-up. One often-cited
cohort reported an approximately twofold difference; observational
findings cannot establish that Thymalin caused the difference.
Russian literature also reports changes in immune measures,
infection rates and broader geroprotective outcomes. Lifespan
extension and broad anti-aging effects remain preliminary claims.
Evidence Limitations
Much of the available clinical literature comes from Russia and is
associated with a limited number of research groups. Evidence
includes observational and open-label reports, with independent
replication in large, rigorous Western trials lacking.
Some long-term reports involved other thymic or pineal products in
combination. They should not be interpreted as proof that Thymalin
alone extends lifespan or produces broad anti-aging effects.
Safety & Regulatory Status
Thymalin is described as generally well-tolerated in available Russian
clinical reports; mild injection-site reactions are among the effects
noted. The published evidence is not sufficient to establish long-term
safety, and serious-event reporting in limited studies should not be
treated as proof of safety.
Thymalin is not FDA-approved for any indication in the United States.
The FDA has identified a Thymalin product marketed in the United States
as an unapproved new drug.
The supplied information reports that a Thymalin pharmaceutical product
is used in Russia for certain indications. Approval of a particular
regional pharmaceutical product does not apply to research-grade
material, which can differ in composition, manufacturing controls and
quality.
Age & Policy Confirmation
Please confirm your age and review the policies before entering.
![Glutathione [1500mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/gulathatione-300x300.jpg)
![KPV (Lysine-Proline-Valine) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/kpv-300x300.jpg)
Reviews
There are no reviews yet.